Conversation with The Cancer Letter Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter Novartis’s Hirawat: “It’s a continuous dialogue that goes on on a daily basis” July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter NCI’s Rosenberg: Tumor infiltrating lymphocytes offer a strategy for treating recalcitrant solid cancers July 13, 2018Vol.44 No.28By Matthew Bin Han Ong
Conversation with The Cancer Letter How the Rabson “practice” helped more than 14,000 patients in 55 years July 06, 2018Vol.44 No.27By Paul Goldberg
Conversation with The Cancer LetterFree Prasad: FDA has confused merely approving drugs with making the world a better place June 22, 2018Vol.44 No.25By Paul Goldberg
Conversation with The Cancer LetterFree Abrams: Only about 20-30 percent of the group might benefit from chemotherapy June 08, 2018Vol.44 No.23By Paul Goldberg
Conversation with The Cancer LetterFree AU Beirut’s Saab: Kids in the region now have access to treatment similar to Western countries June 01, 2018Vol.44 No.22By Matthew Bin Han Ong
Conversation with The Cancer LetterFree St. Jude’s Rodriguez-Galindo: Someday, all children will have the same chances for cure June 01, 2018Vol.44 No.22By Matthew Bin Han Ong
Conversation with The Cancer Letter Six months at MD Anderson:Pisters announces organizational change May 25, 2018Vol.44 No.21By Paul Goldberg
Conversation with The Cancer LetterFree Olive: It’s true, gynecologists don’t biopsy masses as much as other surgeons May 18, 2018Vol.44 No.20By Matthew Bin Han Ong
